Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
Gross Profit Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+223.6%
5Y CAGR+105.9%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
+223.6%/yr
Quarterly compound
5Y CAGR
+105.9%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
37x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 585.06% |
| Q3 2025 | -85.37% |
| Q2 2025 | 2.24% |
| Q1 2025 | 5.06% |
| Q4 2024 | 14.12% |
| Q3 2024 | 376.89% |
| Q2 2024 | -3.14% |
| Q1 2024 | 12.90% |
| Q4 2023 | -81.89% |
| Q3 2023 | -7.73% |
| Q2 2023 | 6.10% |
| Q1 2023 | 13.53% |
| Q4 2022 | 17.26% |
| Q3 2022 | -1.75% |
| Q2 2022 | 3.08% |
| Q1 2022 | 7.61% |
| Q4 2021 | 15.13% |
| Q3 2021 | -6.96% |
| Q2 2021 | 5.30% |
| Q1 2021 | 2.11% |
| Q4 2020 | 15.80% |
| Q3 2020 | -3.38% |
| Q2 2020 | -10.86% |
| Q1 2020 | 2.20% |
| Q4 2019 | 1.67% |
| Q3 2019 | -4.05% |
| Q2 2019 | 4.35% |
| Q1 2019 | 8.33% |
| Q4 2018 | 3.35% |
| Q3 2018 | -7.87% |
| Q2 2018 | 12.92% |
| Q1 2018 | 3.87% |
| Q4 2017 | 11.12% |
| Q3 2017 | -10.64% |
| Q2 2017 | 1.47% |
| Q1 2017 | 9.47% |
| Q4 2016 | 25.23% |
| Q3 2016 | -16.99% |
| Q2 2016 | 1.94% |
| Q1 2016 | 12.16% |